Randomised, double-blind, parallel-group, placebo-controlled, fixed dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult patients with Major Depressive Disorder (MDD) - 14122A Protocol. Cognition PoC

H. Lundbeck A/S0 个研究点目标入组 600 人开始时间: 2011年10月18日最近更新: 2014年1月27日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: H. Lundbeck A/S
入组人数: 600

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•The patient is an inpatient in a psychiatric hospital or an outpatient at a psychiatric setting at the time of the study entry.
•The patient is diagnosed with recurrent MDD according to DSM-IV-TR™ criteria (classification code 296.3x). The current MDE should be confirmed using the Mini International Neuropsychiatric Interview (MINI).
•The patient has received prescribed treatment for a previous episode of depression.
•The patient has a MADRS total score =26.
•The reported duration of the current MDE is at least 3 months.
•Other protocol-defined inclusion criteria apply.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 585
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

排除标准

•The patient has a score =70 on the DSST (numbers correct), =42 on the RAVLT (learning) and =14 on the RAVLT (memory) at the Baseline Visit.
•The patient has any current Axis I disorder (DSM-IV-TR™ criteria) other than MDD, confirmed using the MINI.
•The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features.
•The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
•The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
•The patient is diagnosed with reading disability (dyslexia).
•The patient is at significant risk of suicide or has a score =5 on Item 10 (suicidal thoughts) of the MADRS, or has attempted suicide <6 months prior to the Screening Visit.
•The patient has received electroconvulsive therapy <6 months prior to the Screening Visit.
•The current depressive symptoms are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each at the recommended dose.
•The patient has a history of moderate or severe head trauma (for example, loss of consciousness for more than 1 hour) or other neurological disorders or systemic medical diseases that are, in the opinion of the investigator, likely to affect central nervous system functioning.
•The patient has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, that has not been in remission for >5 years prior to the first drug dose.
•The patient has a clinically significant unstable illness (Examples in protocol).
•The patient has, at the Screening Visit, an abnormal ECG that is, in the investigator's opinion, clinically significant.
•The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.
•The patient has previously been exposed to Lu AA21004.
•Other protocol-defined exclusion criteria apply.

研究者

发起方

H. Lundbeck A/S

相似试验

进行中（未招募）

不适用

Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo in the treatment of depression in patients with Bipolar I or II DisorderBipolar Depression at Phase II study with patients. Lu AA34893 is a novel compound under development by H. Lundbeck A/S as an antidepressant.MedDRA version: 9.1Level: LLTClassification code 10004936Term: Bipolar depression

EUCTR2007-002551-17-SEH. Lundbeck a/s600

进行中（未招募）

1 期

Study of Lu AE58054 in Patients with Mild-moderate Alzheimer's disease treated with DonepezilAlzheimer´s DiseaseMedDRA version: 18.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852

EUCTR2012-004764-22-EEH. Lundbeck A/S840

进行中（未招募）

1 期

Study of Lu AE58054 in Patients with Mild-moderate Alzheimer's disease treated with DonepezilAlzheimer´s DiseaseMedDRA version: 17.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852

EUCTR2012-004764-22-HRH. Lundbeck A/S840

进行中（未招募）

1 期

EUCTR2012-004764-22-PTH. Lundbeck A/S840

进行中（未招募）

1 期

Study of Lu AE58054 in Patients With Mild-moderate Alzheimer's Disease Treated With DonepezilAlzheimer’s diseaseMedDRA version: 17.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852

EUCTR2012-004763-45-DEH. Lundbeck A/S930